Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vortioxetine for the Treatment of Hoarding Disorder
NCT04035850 · Noam Soreni · PHASE3 · withdrawn · last registry update 2024-02-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID-19 pandemic” | – | Registry record, Noam Soreni |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-29Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., 3-6mg QLM1016 + 10-20 mg Aripiprazole oral solution film (NCT06799559)
- 2025-01-20Also stopped (withdrawn): Children's Hospital of Fudan University, Drug Aripiprazole (NCT05361993)
- 2025-01-16Results posted on the registry: Brain and Cognition Discovery Foundation, Vortioxetine + Placebo (NCT05047952)
- 2024-11-20Phase 3 first posted: Shanghai Changzheng Hospital, Carvedilol and alverine (NCT06696248)
- 2024-11-14Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., Brexpiprazole + Placebo (NCT03620981)
- 2024-10-21Results posted on the registry: Technical University of Munich, Olanzapine or amisulpride (NCT01029769)
- 2024-10-03Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole (NCT04186403)
- 2024-09-26Also stopped (withdrawn): Massachusetts General Hospital, Buspirone (NCT03432065)
- 2024-09-19Results posted on the registry: Massachusetts General Hospital, Buspirone (NCT04807517)
- 2024-09-19Results posted on the registry: All India Institute of Medical Sciences, Bhubaneswar, Amisulpride + Olanzapine-Fluoxetine Combination (NCT04876521)
- 2024-09-19Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., Brexpiprazole (NCT03724942)
- 2024-09-19Phase 3 first posted: Chengdu Kanghong Pharmaceutical Group Co., Ltd., Hydrochloride Carliprazine capsules + Aripiprazole tablets (NCT06589817)
- 2024-09-19Results posted on the registry: University of Texas Southwestern Medical Center, Aripiprazole + Placebo (NCT02918370)
- 2024-09-19Results posted on the registry: Elizabeth Berry-Kravis, 5-Hydroxytryptophan + Ergoloid Mesylates (NCT05030129)
- 2024-09-05Phase 3 first posted: Benaroya Research Institute, Amisulpride IV Prevention + Amisulpride IV Treatment (NCT06585540)
- 2024-08-20Phase 3 first posted: Future University in Egypt, Vortioxetine 20Mg Tab (NCT06561438)
- 2024-08-09Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., Brexpiprazole + Placebo (NCT03697603)
- 2024-08-05Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., 2mg conventional tablet, once-weekly tablets (NCT04118127)
- 2024-07-31Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Placebo IEM tablet + Abilify MyCite® (NCT06372210)
- 2024-07-18Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole (NCT04100096)
- 2024-07-01Phase 3 first posted: Louisiana State University Health Sciences Center Shreveport, Lumateperone 42 mg + Risperidone 2 mg (NCT06482554)
- 2024-06-28Also stopped (withdrawn): Massachusetts General Hospital, Buspirone + Placebo (NCT01395953)
- 2024-06-25Phase 3 first posted: Shanghai Changzheng Hospital, Alverine (NCT06473493)
- 2024-06-24Phase 3 first posted: Shanghai Changzheng Hospital, Alverine + Carvedilol (NCT06470386)
- 2024-06-24Also stopped (withdrawn): University of California, Los Angeles, Amisulpride 50 MG (NCT05956600)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision